Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07504172Not Yet Recruiting

Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity

Role: collaborator

NCT07156552Not ApplicableRecruiting

Protein Supplementation and Resistance Training to Prevent Fat-Free Mass Loss Following Metabolic-Bariatric Surgery

Role: collaborator

NCT04902625Phase 4Unknown

Use of Mysimba in Patients With Weight Regain After Bariatric Surgery

Role: collaborator

NCT04883268Not ApplicableCompleted

Focusing on Body Functionality After Bariatric Surgery

Role: collaborator

NCT04643301Not ApplicableWithdrawn

Liraglutide for Low-responders After Bariatric Surgery

Role: collaborator

All 5 trials loaded